ImmuPharma plc

DB:25I Stock Report

Market Cap: €5.9m

ImmuPharma Management

Management criteria checks 3/4

ImmuPharma's CEO is Tim McCarthy, appointed in Jul 2021, has a tenure of 3.42 years. total yearly compensation is £294.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth €20.98K. The average tenure of the management team and the board of directors is 2.3 years and 11.4 years respectively.

Key information

Tim McCarthy

Chief executive officer

UK£294.0k

Total compensation

CEO salary percentage100.0%
CEO tenure3.4yrs
CEO ownership0.4%
Management average tenure2.3yrs
Board average tenure11.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tim McCarthy's remuneration changed compared to ImmuPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£2m

Mar 31 2024n/an/a

-UK£3m

Dec 31 2023UK£294kUK£294k

-UK£3m

Sep 30 2023n/an/a

-UK£3m

Jun 30 2023n/an/a

-UK£3m

Mar 31 2023n/an/a

-UK£3m

Dec 31 2022UK£107kUK£107k

-UK£4m

Sep 30 2022n/an/a

-UK£5m

Jun 30 2022n/an/a

-UK£6m

Mar 31 2022n/an/a

-UK£7m

Dec 31 2021UK£575kUK£287k

-UK£8m

Sep 30 2021n/an/a

-UK£8m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£7m

Dec 31 2020UK£260kn/a

-UK£7m

Sep 30 2020n/an/a

-UK£6m

Jun 30 2020n/an/a

-UK£5m

Mar 31 2020n/an/a

-UK£6m

Dec 31 2019UK£260kn/a

-UK£6m

Sep 30 2019n/an/a

-UK£7m

Jun 30 2019n/an/a

-UK£7m

Mar 31 2019n/an/a

-UK£7m

Dec 31 2018UK£260kn/a

-UK£7m

Sep 30 2018n/an/a

-UK£7m

Jun 30 2018n/an/a

-UK£7m

Mar 31 2018n/an/a

-UK£7m

Dec 31 2017UK£260kn/a

-UK£6m

Compensation vs Market: Tim's total compensation ($USD368.54K) is about average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim McCarthy (68 yo)

3.4yrs

Tenure

UK£294,000

Compensation

Mr. Timothy Paul McCarthy, XIV, also known as Tim, MBA, FCCA, is Independent Non-Executive Chairman at 4basebio PLC. He co-founded Alizyme PLC in 1995. Mr. McCarthy serves as the Chairman of ImmuPharma plc...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy McCarthy
Chairman & CEO3.4yrsUK£294.00k0.36%
€ 21.0k
Timothy Franklin
COO & Director4.9yrsUK£252.00k0.13%
€ 7.4k
Ashley Clarke
Group CFO & Company Secretaryno datano datano data
Jean-Marie Geiger
Head of Clinical Developmentno datano datano data
Laura Mauran-Ambrosino
Chief Scientific Officer of ImmuPharma Biotech2.3yrsno datano data
Lara Sucheston-Campbell
Head of Clinical & Medical Affairs1.8yrsno datano data

2.3yrs

Average Tenure

Experienced Management: 25I's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy McCarthy
Chairman & CEO9.3yrsUK£294.00k0.36%
€ 21.0k
Timothy Franklin
COO & Director3.4yrsUK£252.00k0.13%
€ 7.4k
Lee Simon
Member of Scientific Advisory Board11.4yrsno datano data
Vibeke Strand
Member of Scientific Advisory Board11.4yrsno datano data
David Isenberg
Member of Scientific Advisory Board11.4yrsno datano data
Daniel Wallace
Member of Scientific Advisory Board11.4yrsno datano data
Cees Kallenberg
Member of Scientific Advisory Board11.4yrsno datano data
Sebastien R. Goudreau
Independent Non-Executive Director1.3yrsUK£1.17k0.036%
€ 2.1k

11.4yrs

Average Tenure

64yo

Average Age

Experienced Board: 25I's board of directors are seasoned and experienced ( 11.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImmuPharma plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander PyeCavendish
null nullCavendish
Navid MalikCavendish Historical (Cenkos Securities)